ConvaTec Group Plc
Scrip Dividend - total issued shares
Reading, United Kingdom (27 September 2019)
On 31 July 2019, the Board of Directors of ConvaTec Group Plc ("ConvaTec" or "the Company") declared an interim dividend of 1.717 cents per share (the "interim dividend"). This interim dividend is to be paid on 17 October 2019 to shareholders on the share register as at 6 September 2019 ("record date"). The dividend is payable in cash in sterling to holders of ordinary shares. On 1 August 2019, the Company announced that a scrip dividend would be made available for this interim dividend allowing shareholders to elect to receive their dividend in the form of new ordinary shares. The calculation price for the scrip dividend was announced on 12 September 2019.
It is confirmed that 6,159,842 ordinary shares of 10 pence each will be allotted and issued on 17 October 2019 by the Company to those shareholders who elected to receive the scrip dividend alternative. The shares will rank pari passu with the existing issued ordinary shares of the Company. Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List and to the London Stock Exchange for the shares to be admitted to trading.
Dealings in the shares issued under the scrip dividend scheme is expected to commence on 17 October 2019.
Details of the scrip dividend scheme are available at www.convatecgroup.com/investors.
TIMETABLE
Key dates in respect of the scrip dividend scheme for the interim dividend are:
Ex-dividend Date |
5 September 2019 |
Record Date |
6 September 2019 |
Scrip calculation price determined |
5-11 September 2019 (inclusive) |
Scrip calculation price available and announced |
12 September 2019 |
Mandate delivery deadline for Shares held in uncertificated form |
3.00 p.m. on 23 September 2019 |
Mandate delivery deadline for Shares held in certificated form |
5.00 p.m. on 23 September 2019 |
Announcement of the total amount of new shares to be issued |
27 September 2019 |
Dividend payment date |
17 October 2019 |
Dispatch of statement in accordance with section 7 of Scheme |
17 October 2019 |
Rules and share certificates, CREST accounts credited/updated,
and first day of dealings in New Shares
Enquiries
Analysts, Investors and Media
John Crosse, VP Investor Relations, ConvaTec +44 (0)7500 141 435
Mark Reynolds, Director Investor Relations, ConvaTec +44 (0)7551 036 625
investorrelations@convatec.com
Alastair Elwen, Finsbury +44 (0)207 251 3801
Legal Entity Identifier Code: 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
# # #
END